Abstract
We report the case of a T3 prostate cancer in a 70-year-old white man. Hormone therapy represents a prominent branch in the treatment of locally advanced and metastatic prostate cancer. Gonadotropin-releasing hormone agonists have been proven to have a double effect on androgen metabolism: an initially stimulating, followed by an inhibitory, effect on the pituitary gland. This phenomenon may be noxious in the case of gonadotroph adenoma, with subsequent symptoms of intracranial hypertension. Gonadotropin-releasing hormone antagonists (abarelix), by avoiding the flare-up reaction, might be used in such instances.
MeSH terms
-
Adenocarcinoma / complications
-
Adenocarcinoma / diagnosis
-
Adenocarcinoma / drug therapy*
-
Adenoma / chemically induced*
-
Adenoma / diagnosis
-
Aged
-
Antineoplastic Agents, Hormonal / adverse effects*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Biopsy
-
Diagnosis, Differential
-
Gonadotropin-Releasing Hormone / agonists*
-
Humans
-
Leuprolide / adverse effects*
-
Leuprolide / therapeutic use
-
Magnetic Resonance Imaging
-
Male
-
Pituitary Neoplasms / chemically induced*
-
Pituitary Neoplasms / diagnosis
-
Prostatic Neoplasms / complications
-
Prostatic Neoplasms / diagnosis
-
Prostatic Neoplasms / drug therapy*
-
Tomography, X-Ray Computed
Substances
-
Antineoplastic Agents, Hormonal
-
Gonadotropin-Releasing Hormone
-
Leuprolide